Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuan-Ching Chang

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Breast Cancer Research and Treatment|February 3, 2022
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patientsPo-Han Lin, Shin-Cheh Chen, Ling-Ming Tseng, et al.
Nature Medicine|October 7, 2016
Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitorsYi Du, Hirohito Yamaguchi, Yongkun Wei, et al.
The New England Journal of Medicine|December 10, 2025
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast CancerSibylle Loibl, Yeon Hee Park, Zhiming Shao, et al.
Journal of Breast Cancer|July 6, 2026
2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer ManagementJiun-I Lai, Chih-Chiang Hung, Chin-Yao Lin, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Breast Cancer Research and Treatment|February 3, 2022
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patientsPo-Han Lin, Shin-Cheh Chen, Ling-Ming Tseng, et al.
Nature Medicine|October 7, 2016
Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitorsYi Du, Hirohito Yamaguchi, Yongkun Wei, et al.
The New England Journal of Medicine|December 10, 2025
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast CancerSibylle Loibl, Yeon Hee Park, Zhiming Shao, et al.
Journal of Breast Cancer|July 6, 2026
2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer ManagementJiun-I Lai, Chih-Chiang Hung, Chin-Yao Lin, et al.
Pageof 8